Skip to content

TVARDI THERAPEUTICS, INC.

TVRD

CIK 0001346830

← back to feed
Revenue (TTM)
$8.25M
−66.0% YoY Q1 May 2026
Net Income (TTM)
−$17.74M
+38.0% YoY Q1 May 2026
EPS Diluted (TTM)
−$6.04
+71.5% YoY Q1 May 2026
Gross Margin
100.0%
Q1 May 2026
Operating Margin
-317.7%
Q1 May 2026
Net Margin
-215.0%
Q1 May 2026
Free Cash Flow (TTM)
−$79.51M
Q1 May 2026
Cash
$19.85M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
9.38M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings